Nature of the business (Details) $ in Thousands	1 Months Ended		12 Months Ended
	Feb. 29, 2024 USD ($) shares	Jun. 30, 2023 USD ($) shares	Dec. 31, 2023 USD ($) item	Dec. 31, 2022 USD ($)
Number of clinical assets | item			1
Number of preclinical assets | item			3
Net loss			$ 106,806	$ 36,896
Accumulated deficit			222,807	$ 116,001
Proceeds from issuance of common stock			$ 34
Subscription Agreements
Proceeds from issuance of common stock		$ 125,000
Issuance of common stock ( in shares) | shares		21,690,871
Public offering | Subsequent Event [Member]
Proceeds from issuance of common stock	$ 230,000
Issuance of common stock ( in shares) | shares	11,500,000